More information
Description
This bilateral initiative aims to develop a pan-cancer therapeutic based on HH2CAR, a novel immunotherapy targeting aberrant sialylated glycan structures found on malignant cells. The HH2 antibody, identified at the Radium Hospital, recognizes unique glycan alterations associated with cancer. These alterations make glycans ideal selective targets for cancer therapy. Dr. Wälchli’s team has created HH2CAR, while Dr. Reis’ group has developed glycoengineered cancer cell models with varying sialylated structures to study HH2CAR''s efficacy.
The project has two specific aims:
Characterize HH2